A Non-Randomized Study of Patisiran in Patients with hATTR Cardiac Amyloidosis
Latest Information Update: 07 Sep 2020
At a glance
- Drugs Patisiran (Primary) ; Diflunisal
- Indications Amyloidosis
- Focus Therapeutic Use
- 07 Sep 2020 New trial record
- 03 Sep 2020 According to an Alnylam Pharmaceuticals media release, this study was led by the University College Hospital in the UK.
- 03 Sep 2020 According to an Alnylam Pharmaceuticals media release, results from this study were presented at the European Society of Cardiology (ESC) 2020 Congress, held virtually 29th Aug-1st Sep 2020.